Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PIONEER: atacicept in multiple autoimmune glomerular diseases
2024-518465-10-00Phase 2Authorised
- Sponsor
- Vera Therapeutics
- Start
- Dec 2025
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 10
01
Overview
Phase 2 trial of atacicept in autoimmune glomerulonephritis, IgA nephropathy (IgAN), idiopathic membranous glomerulonephritis (IMG) and 1 more, sponsored by Vera Therapeutics. Primary endpoints: Safety through Week 52, Change from baseline in UPCR at Week 36 and 1 more. Planned start Dec 2025; status: authorised.
02
Drugs
atacicept
03
Conditions
autoimmune glomerulonephritisIgA nephropathy (IgAN)idiopathic membranous glomerulonephritis (IMG)nephrosis
Beyond the preview
Go deeper on 2024-518465-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518465-10-00.